Price Analysis of Systemic Therapies and Transarterial Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma.

Q2 Medicine
Journal of market access & health policy Pub Date : 2025-05-27 eCollection Date: 2025-06-01 DOI:10.3390/jmahp13020025
Abimbola O Williams, Nicholas Anderson, Young-Gwan Gwon, Wendy Wifler
{"title":"Price Analysis of Systemic Therapies and Transarterial Radioembolization for Treatment of Unresectable Hepatocellular Carcinoma.","authors":"Abimbola O Williams, Nicholas Anderson, Young-Gwan Gwon, Wendy Wifler","doi":"10.3390/jmahp13020025","DOIUrl":null,"url":null,"abstract":"<p><p>Systemic therapy (ST) and transarterial radioembolization (TARE) are widely used treatments for advanced-stage hepatocellular carcinoma (HCC). This study quantified the significant variability in treatment costs for unresectable HCC from payer and provider perspectives. An Excel-based price analysis model was developed to estimate the prices of ST and TARE over a 21-month time horizon using 2015-2021 data. Median prices were calculated from Medicare Average Sales Price (ASP), provider Wholesale Acquisition Cost (WAC), and Average Wholesale Price (AWP). Sensitivity analyses evaluated price fluctuations associated with a ±10% variation in treatment duration. ST prices demonstrated marked variability across perspectives, with the median ASP at $175,625, WAC at $198,719, and AWP at $262,892. However, TARE prices were stable, ranging from $21,594 to $24,052. Sensitivity analyses revealed that treatment duration variation resulted in price changes of $35,000-$50,000 for ST, compared with ~$5000 for TARE. The variability in ST pricing was driven by treatment duration and drug-specific pricing mechanisms, particularly immunotherapy-based regimens, which accounted for the higher cost range. Conversely, TARE's consistent pricing is attributed to standardized procedural costs. Substantial variability exists in ST prices compared with the consistent costs of TARE, underscoring the economic advantage of TARE in appropriate clinical contexts.</p>","PeriodicalId":73811,"journal":{"name":"Journal of market access & health policy","volume":"13 2","pages":"25"},"PeriodicalIF":0.0000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12194767/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of market access & health policy","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/jmahp13020025","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Systemic therapy (ST) and transarterial radioembolization (TARE) are widely used treatments for advanced-stage hepatocellular carcinoma (HCC). This study quantified the significant variability in treatment costs for unresectable HCC from payer and provider perspectives. An Excel-based price analysis model was developed to estimate the prices of ST and TARE over a 21-month time horizon using 2015-2021 data. Median prices were calculated from Medicare Average Sales Price (ASP), provider Wholesale Acquisition Cost (WAC), and Average Wholesale Price (AWP). Sensitivity analyses evaluated price fluctuations associated with a ±10% variation in treatment duration. ST prices demonstrated marked variability across perspectives, with the median ASP at $175,625, WAC at $198,719, and AWP at $262,892. However, TARE prices were stable, ranging from $21,594 to $24,052. Sensitivity analyses revealed that treatment duration variation resulted in price changes of $35,000-$50,000 for ST, compared with ~$5000 for TARE. The variability in ST pricing was driven by treatment duration and drug-specific pricing mechanisms, particularly immunotherapy-based regimens, which accounted for the higher cost range. Conversely, TARE's consistent pricing is attributed to standardized procedural costs. Substantial variability exists in ST prices compared with the consistent costs of TARE, underscoring the economic advantage of TARE in appropriate clinical contexts.

全身治疗和经动脉放射栓塞治疗不可切除肝癌的价格分析。
全身治疗(ST)和经动脉放射栓塞(TARE)是晚期肝细胞癌(HCC)广泛使用的治疗方法。本研究从付款人和提供者的角度量化了不可切除HCC治疗费用的显著差异。开发了基于excel的价格分析模型,使用2015-2021年的数据估算了21个月时间范围内ST和TARE的价格。中位数价格由医疗保险平均销售价格(ASP)、供应商批发获取成本(WAC)和平均批发价格(AWP)计算得出。敏感性分析评估了与治疗时间±10%变化相关的价格波动。ST价格在不同角度表现出明显的差异,平均均价为175,625美元,WAC为198,719美元,AWP为262,892美元。然而,TARE价格稳定,在21,594美元至24,052美元之间。敏感性分析显示,治疗时间的变化导致ST的价格变化为35,000- 50,000美元,而TARE的价格变化为~ 5000美元。ST定价的变化是由治疗时间和药物特异性定价机制驱动的,特别是基于免疫治疗的方案,这导致了更高的成本范围。相反,TARE的一致性定价归因于标准化的程序成本。与TARE的一贯成本相比,ST的价格存在很大的可变性,强调了TARE在适当的临床环境中的经济优势。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.90
自引率
0.00%
发文量
0
审稿时长
14 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信